|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.26 USD | -0.94% |
|
-5.16% | -16.34% |
Business description: Bio-Techne Corporation
- biological and chemical reagents and analysis tools (71.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (28.4%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ;
- other (0.3%).
Net sales are distributed geographically as follows: the United States (56%), the United Kingdom (4.5%), Europe/Middle East/Africa (21.8%), China (8.3%), Asia/Pacific (6.3%) and other (3.1%).
Number of employees: 3,100
Sales by Activity: Bio-Techne Corporation
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Protein Sciences | 705M | 832M | 846M | 831M | 870M |
Diagnostics and Spatial Biology | 228M | 275M | 293M | 326M | 346M |
Other Revenue | - | - | - | 4.15M | 4.15M |
Intersegment Revenue | -1.28M | -1.56M | -1.65M | -2.39M | -1.02M |
Geographical breakdown of sales: Bio-Techne Corporation
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
United States | 502M | 614M | 642M | 658M | 683M |
EMEA, Excluding United Kingdom | 204M | 219M | 220M | 241M | 266M |
Greater China | 87.56M | 112M | 114M | 99.47M | 100M |
APAC, Excluding Greater China | 69.01M | 76.14M | 73.19M | 73.9M | 77.26M |
United Kingdom | 40.94M | 48.64M | 49.46M | 50.01M | 54.83M |
Rest of World | 27.17M | 35.22M | 37.49M | 36.5M | 37.55M |
Executive Committee: Bio-Techne Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 58 | 2024-01-31 |
James Hippel
DFI | Director of Finance/CFO | 54 | 2014-03-31 |
David Clair
IRC | Investor Relations Contact | - | 2019-09-30 |
Steve Crouse
PRN | Corporate Officer/Principal | 52 | 2021-02-28 |
Matthew McManus
PRN | Corporate Officer/Principal | 56 | 2024-01-07 |
Composition of the Board of Directors: Bio-Techne Corporation
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 2012-11-01 | |
John Higgins
BRD | Director/Board Member | 55 | 2009-05-18 |
Alpna Seth
BRD | Director/Board Member | 62 | 2017-10-25 |
Joseph Keegan
BRD | Director/Board Member | 72 | 2017-10-25 |
Rupert Vessey
BRD | Director/Board Member | 60 | 2019-06-25 |
Kim Kelderman
BRD | Director/Board Member | 58 | 2023-10-31 |
Julie Bushman
BRD | Director/Board Member | 64 | 2020-07-30 |
Judith Klimovsky
BRD | Director/Board Member | 68 | 2024-04-23 |
Amy Herr
BRD | Director/Board Member | 50 | 2024-12-31 |
Company details: Bio-Techne Corporation
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.94% | -5.16% | -21.55% | -25.36% | 9.39B | |
| -0.84% | -4.46% | -5.33% | +12.00% | 46.35B | |
| +1.37% | +0.47% | +12.39% | +8.37% | 38.48B | |
| -0.57% | -3.19% | +74.01% | +62.86% | 35.5B | |
| +0.54% | +2.25% | +10.68% | +17.47% | 27.77B | |
| +0.96% | +3.92% | +65.78% | +175.14% | 15.95B | |
| +0.81% | +0.04% | +69.09% | +230.15% | 15.18B | |
| +2.19% | +2.24% | -10.49% | -2.48% | 14.5B | |
| -1.61% | -3.24% | +71.01% | - | 13.14B | |
| +0.65% | -3.26% | +108.32% | +111.04% | 12.82B | |
| Average | +0.33% | -1.07% | +37.39% | +65.47% | 22.91B | |
| Weighted average by Cap. | +0.14% | -1.25% | +31.51% | +51.08% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TECH Stock
- Company Bio-Techne Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition